Attorney Docket No.: PM (DC-0251)
Inventor: Wade and Demain

Serial No.: 09/720,078
Filing Date: July 25, 2001

Page 8

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

Claim 1 (currently amended): A method for enhancing or suppressing at least the humoral immune response or CD4 Th1 Th1 immune response to a target antigen comprising administering the following:

- (i) a conjugate comprising a selected antigen, which is directly or indirectly attached to an antibody that specifically binds to a molecule which is expressed by an antigen-presenting cell (APC); and
- (ii) an anti-CD40 antibody, wherein the antigen-antibody conjugate of (i) and the anti-CD40 antibody of (ii) are administered simultaneously or substantially contemporaneously thereby synergistically enhancing or suppressing at least the humoral immune response or CD4 Th1 immune response to the target antigen.

Claim 2 (original): The method of Claim 1 wherein the antibody attached to said antigen is selected from the group consisting of an anti-MHC class II antibody, an anti-MHC class I antibody, an anti-CD11c antibody, an anti-dentritic cell antigen antibody, an anti-follicular cell antigen antibody, and an anti-Fc molecule antibody.

Claims 3-4 (canceled).

Attorney Docket No.:

PM (DC-0251)

Inventor:

Wade and Demain

Serial No.: Filing Date:

09/720,078 July 25, 2001

Page 9

Claim 5 (original): The method of Claim 1, which is effected in vivo.

Claim 6 (original): The method of Claim 5, wherein said method is effected in an aged or immuno-compromised individual.

Claim 7 (original): The method of Claim 6, wherein the treated individual is a human subject fifty years or older.

Claim 8 (original): The method of Claim 6, which is used for the treatment of viral infection, bacterial injection or cancer.

Claim 9 (currently amended): The method of Claim 1, wherein said antigen is expressed by a moiety selected from the group consisting of a tumor or cancer cell, a virus, a pathogen, a bacterium, a <u>fungi</u> <u>fungus</u>, and a toxin.

Claim 10 (original): The method according to Claim 9, wherein said cancer or tumor cell is selected from the group consisting of prostate, breast, ovarian, lung, head and neck, uterine, and leukemia.

Claim 11 (currently amended): The method according to Claim 9, wherein said virus is selected from the group consisting of a papillomavirus, RSV, herpes virus, in influenza virus, a hepatitis virus, a polio virus, and HIV virus.

Claim 12 (original): The method according to Claim 1, wherein the antigen-antibody conjugate of (i) and the anti-CD40 antibody are administered together.

Attorney Docket No.:

PM (DC-0251)

Inventor:

Wade and Demain

Serial No.: Filing Date:

09/720,078

Page 10

July 25, 2001

Claim 13 (original): The method according to Claim 1, wherein the antigen is directly attached to said antibody.

Claim 14 (original): The method according to Claim 13, wherein said direct attachment comprises covalent attachment of the antigen and the antibody.

Claim 15 (original): The method according to Claim 1, wherein the administered antigen-antibody conjugate of (i) and the anti-CD40 antibody are contained in the same composition.

Claim 16 (original): The method of Claim 1 which is used to induce a protective Th1 cell-mediated immune response against a bacterial disease or protozoan disease.

Claim 17 (currently amended): The method of Claim 1 which is used to treat <a href="leishmanin????">leishmaniasis</a>, <a href="leishmaniasis">leishmaniasis</a>, <a href="leishmaniasis">listeriosis</a>, <a href="Lyme's disease">Lyme's disease</a>, <a href="leprosy">leprosy</a>, or tuberculosis infection.

Claims 18-30 (canceled).